These two compoundsblock infection by binding to EBOV-GP, acting as antiviral entry inhibitors.22,23 Viral entry inhibition by disrupting the NPC1/EBOV-GP interactionhas been observed with several adamantane derivatives, including compound3.47 and its variants, which act in an NPC1-dependent manner12,24−26 (Figure 1). This evidence concerns the gene NPC1 and infection.